Technology appraisal programme
NICE recommends treatments for mantle cell lymphoma and chronic lymphocytic leukaemia
The treatments are for eligible adults in England and Wales
NICE recommends Genmab’s Tivdak for recurrent or metastatic cervical cancer
It is estimated that 3,300 women are diagnosed with cervical cancer in the UK each year
Sanofi and Regeneron’s Dupixent receives positive NICE final draft guidance for COPD
Around 1.4 million people in the UK are diagnosed with COPD, with two million thought to be undiagnosed
ViiV Healthcare receives NICE recommendation for HIV prevention therapy
The treatment is the first and only long-acting HIV prevention option available on the NHS in England and Wales
Pfizer’s Lorviqua recommended by NICE for lung cancer
Lung cancer is the leading cause of cancer-related deaths worldwide
NICE recommends ALK’s immunotherapy to target underlying cause of hay fever
An estimated 26,800 people in England with moderate-to-severe cases could benefit from Itulazax
NICE recommends BeOne’s Brukinsa to treat mantle cell lymphoma on NHS
Approximately 600 people are affected by the form of non-Hodgkin lymphoma every year in the UK
Novartis’ Kisqali recommended by NICE to treat broad early breast cancer population
The drug was previously available only for patients whose cancer had spread to nearby lymph nodes
Vertex’s triple combination cystic fibrosis therapy Alyftrek recommended by NICE
The rare inherited disease affects approximately 11,000 people in the UK
Boehringer’s Spevigo recommended by NICE for generalised pustular psoriasis
The rare form of psoriasis can lead to serious complications such as sepsis and heart failure
AstraZeneca’s Forxiga recommended by NICE for wider chronic kidney disease use
An estimated 7.2 million people in the UK are living with the progressive condition
NHS patients to access Theramex’s endometriosis pill following NICE recommendation
The once-a-day drug has been recommended for patients with a history of previous medical or surgical treatment